This paper discusses the data for and against the use of molecular biomarkers as an enrichment strategy in future clinical trials in PAH. This is a call for the collection of prospective data to create a biomarker panel that would then be employed in future trials for PAH.
NIH Workshop Summary from leading experts. A review of precision medicine approaches to treatments for PAH including inadequacies of therapy of PAH using the traditional approach, considerations in the conduct of clinical trials for a precision medicine approach, considerations in the design of clinical trials, and pharmaceutical industry challenges with precision medicine clinical trials.
© Copyright 2021 Tenax Therapeutics. All Rights Reserved.
Site created by Top Shelf Design